1   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.

2   Crown Bioscience and Medical & MBL, today announced the formation of a joint venture.


Discover the infinite power of partnership to drive scientific discovery

Crown Bioscience is a Contract Research Organization (CRO) driven by our mission is to empower our customers to improve human health.

We do this by engaging the finest scientific talent, upholding the highest quality standards, and relentlessly pursuing innovation.

Every day we strive to accelerate and de-risk drug development to help realize a world where every patient gets the right treatment, at the right time.

Oncology Databases

Quickly Find Models to Fit Your Research Needs

Learn More

Latest News

New Crown Bioscience Publication Details Application of In Vitro 3D Organoids with Matched PDX for Clinically Relevant Oncology Drug Development

Read More

Learn more about our services

Therapeutic Areas

Leverage our extensive experience in oncology, immuno-oncology, immune-mediated inflammatory and cystopathic diseases

Learn More

Model Systems

Discover the largest commercially available collection of PDX models as well as our novelin vitro models

Learn More


Utilize our bioinformatics, biomarker analysis, genomics and high content imaging services to advance your preclinical studies

Learn More

Service Types

Accelerate your drug development with our biomarker discovery, efficacy testing, DMPK and pharmacology services

Learn More

Review our published work!

Crown Bioscience is an expert preclinical CRO.

Latest Resources

Latest Factsheet

Lead Identification Screening Services in 3D

Leverage Crown Bioscience's formula for high throughput success.

View Factsheet

Latest Application Note

HCC827 NSCLC Cell Line Derived Xenograft Model

Evaluate immunotherapeutics and agents to overcome drug resistance with our NSCLC EGFR exon 19 deletion resources

View Application Note

Latest Webinar

Preclinical Solutions for Drug Development Targeting Advanced Breast Cancer

Despite the rapid development of new oncology therapies, there is a high unmet need for advanced and aggressive forms of breast cancer.

View Webinar

Latest Blog Posts

November 30, 2022

Applications of Genetically Engineered Organoids and Cell Lines

This post explores applications of genetically engineered organoids and cell lines to expand and accelerate anti-cancer drug discovery and development. We first provide a brief overview of two major methods that are used to develop engineered organoids/cell lines (i.e., lentiviral transduction and PiggyBac), followed by typical workflows for generating these models. Several case studies are presented to showcase their application for target validation and in vitro /in vivo efficacy studies.


November 10, 2022

How 3D In Vitro Organoids Can Enhance the Predictivity of Cancer Drug Discovery

Drug development is a lengthy, risky, and costly endeavor with high candidate attrition. Attrition rates for anticancer agents are much higher than in other therapeutic categories. Only 5% of them are estimated to reach the clinical stage. This very high rate has been attributed in part to the poor translatability of current preclinical data.


October 28, 2022

Leveraging PDX Models for Modeling Metastatic Breast Cancer

Major advances in breast cancer treatment have significantly improved survival rates, but metastatic disease continues to be the leading cause of breast cancer-related deaths. Developing novel therapies for metastatic breast cancer requires preclinical breast cancer models that better-recapitulate important clinical features of the disease, including metastasis.


October 14, 2022

Organoid Biobanks: Living Predictive Models for Cancer Drug Development

The need for more clinically relevant preclinical models has been identified as one of the areas that can help reduce the high attrition rate observed for anticancer drugs. Better models, such as Hubrecht Organoid Technology (HUB) tumor organoids, can drive better decisions in drug discovery by identifying agents that will have the best chances of succeeding in clinical trials. In this post we explore the value of “living” tumor organoid biobanks for identifying anticancer agents with improved clinical relevance.


Ensuring that every patient has the right
treatment at the right time.